Traditional Chinese medicine compound for treating multi-drug-resistant bacterium infection combined pneumonia

By combining traditional Chinese medicines such as reed rhizome with the efficacy of traditional Chinese medicine formulas, the treatment challenge of pneumonia complicated by multidrug-resistant bacterial infection has been solved, achieving the inhibition of drug-resistant bacteria and significant improvement of pneumonia.

CN122056997APending Publication Date: 2026-05-19THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF TCM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610477242.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-13
Publication Date
2026-05-19

AI Technical Summary

Technical Problem

Current technologies are ineffective in treating pneumonia caused by multidrug-resistant bacterial infections, and traditional antibacterial drugs have limited efficacy. Traditional Chinese medicine has potential advantages in this field, but its specific formulations and applications are insufficient.

Method used

This formula uses a traditional Chinese medicine compound composed of reed rhizome, coix seed, peach kernel, winter melon seed, apricot kernel, platycodon root, lepidium seed, prepared licorice root, ephedra, gypsum, jujube, and ginger. It combines the effects of the "Qianjin" reed stem decoction, ephedra, apricot kernel, gypsum and licorice decoction, lepidium and jujube lung-clearing decoction, and pus-draining decoction. It treats phlegm-heat and turbidity in the lungs by clearing heat, resolving phlegm, removing blood stasis, and relieving asthma. It is prepared as granules, oral liquid, or decoction.

Benefits of technology

It significantly inhibits the proliferation of multidrug-resistant Pseudomonas aeruginosa, eliminates drug-resistant bacteria, improves the pathological morphology of lung tissue, regulates the level of inflammatory factors, and achieves effective treatment for pneumonia complicated by multidrug-resistant bacterial infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122056997A_ABST
    Figure CN122056997A_ABST
Patent Text Reader

Abstract

The invention provides a traditional Chinese medicine compound for treating multi-drug-resistant bacterium infection combined pneumonia, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine compound is prepared from Qianjin reed stem decoction, maxingshigan decoction, semen lepidii and jujube lung purging decoction and pus expelling decoction in a combined formula and cut mode. The traditional Chinese medicine compound is specifically prepared from 30-60 g of rhizoma phragmitis, 20-40 g of coix seeds, 5-25 g of peach kernels, 30-60 g of Chinese waxgourd seeds, 5-25 g of almonds, 5-25 g of platycodon grandiflorum, 10-30 g of semen lepidii, 5-20 g of honey-fried licorice roots, 5-20 g of ephedra, 20-40 g of gypsum, 5-25 g of jujubes and 5-25 g of fresh ginger. The whole formula has the effects of diffusing lung qi, reducing phlegm and dampness, removing stasis and turbidity, clearing lung and dissipating heat, reducing phlegm and expelling pus, and relieving asthma and cough, and is suitable for the pathogenesis of pulmonary infection and phlegm-heat obstructing lung. Through verification, the traditional Chinese medicine compound can effectively inhibit the proliferative activity of multi-drug-resistant pseudomonas aeruginosa, has an obvious drug-resistant bacterium removal effect, can effectively improve the general and pathological morphology of lung tissues, regulate and control the inflammatory factor level, exerts a remarkable anti-inflammatory effect, and achieves a good treatment effect on drug-resistant bacterium infection combined pneumonia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine manufacturing technology, specifically to a traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection. Background Technology

[0002] Pneumonia refers to inflammation of the terminal airways, lung interstitium, and alveoli. It has many causes and can progress to severe pneumonia (SP). Severe pneumonia is a serious respiratory infectious disease caused by multiple pathogens. Patients may exhibit sepsis, shock, or even death, seriously threatening their lives and health. The increased use of various antibiotics in SP patients, especially broad-spectrum antibiotics, prolonged treatment cycles, and large doses, can increase the risk of drug resistance mutations in pathogens and the types of drug-resistant bacteria, leading to multidrug-resistant (MDR) bacteria, and potentially even the emergence of superbugs for which no drugs are effective. MDR in SP patients prolongs treatment time, increases treatment costs, and raises the risk of death.

[0003] Multidrug-resistant bacterial (MDR) infections are a major clinical concern, but despite continuous research and development of new antibiotics, they have yet to completely eradicate MDR infections. Some patients may experience symptom exacerbation or infection with other bacterial groups, and traditional treatments have limited clinical efficacy against MDRs. In recent years, Traditional Chinese Medicine (TCM), as a traditional treatment method, has demonstrated potential antibacterial effects in the diagnosis and treatment of MDRs. As the problem of bacterial resistance intensifies, TCM's understanding of MDR severe pneumonia has deepened, identifying its basic pathogenesis as a deficiency of vital energy and an excess of pathogenic factors, with the excess of pathogenic factors mainly manifested as the intermingling of pathological products such as phlegm, heat, and blood stasis. Modern pharmacological research further explains that TCM, with its multi-component and multi-target characteristics, possesses unique advantages and potential in inhibiting pathogen proliferation, reversing bacterial resistance, regulating the body's inflammatory response, and enhancing immunity. Currently, integrated TCM and Western medicine treatment for MDR severe pneumonia is widely used clinically, achieving good clinical results and providing a new strategy for combating bacterial resistance. Summary of the Invention

[0004] (a) Technical problems to be solved

[0005] To address the shortcomings of existing technologies, this invention provides a traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection.

[0006] (II) Technical Solution

[0007] To achieve the above objectives, the present invention provides the following technical solution:

[0008] A traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection, the compound consisting of the following medicinal materials by weight: 30-60g of reed rhizome, 20-40g of coix seed, 5-25g of peach kernel, 30-60g of winter melon seed, 5-25g of apricot kernel, 5-25g of platycodon root, 10-30g of lepidium seed, 5-20g of prepared licorice root, 5-20g of ephedra, 20-40g of gypsum, 5-25g of jujube, and 5-25g of ginger.

[0009] Furthermore, the traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection consists of the following medicinal materials by weight: 40-50g of reed rhizome, 25-35g of coix seed, 10-20g of peach kernel, 40-50g of winter melon seed, 10-20g of apricot kernel, 10-20g of platycodon root, 15-25g of lepidium seed, 5-15g of prepared licorice root, 5-15g of ephedra, 25-35g of gypsum, 10-20g of jujube, and 10-20g of ginger.

[0010] Furthermore, the traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection consists of the following medicinal materials by weight: 45g of reed rhizome, 30g of coix seed, 15g of peach kernel, 45g of winter melon seed, 15g of apricot kernel, 15g of platycodon root, 20g of lepidium seed, 10g of prepared licorice root, 9g of ephedra, 30g of gypsum, 15g of jujube, and 15g of ginger.

[0011] The traditional Chinese medicine compound provided by this invention is used to prepare a drug for treating pneumonia complicated by multidrug-resistant bacterial infection. The drug is made from the above-mentioned weight of traditional Chinese medicinal materials as raw materials, supplemented with pharmaceutically acceptable excipients, and prepared into any one of granules, oral liquid, or decoction.

[0012] The core pathogenesis of pulmonary infections is phlegm-heat and blood stasis obstructing the lungs, impairing their function of dispersing and descending qi. The key pathological products are phlegm, heat, blood stasis, and turbidity. The combination of heat and phlegm obstructs the lung collaterals, hindering the flow of qi and potentially leading to blood stasis. The mutual binding of phlegm, heat, and blood stasis further obstructs the airways, preventing the lung qi from both dispersing and descending, resulting in cough, wheezing, chest pain, and even the development of abscesses (suppurative infections). Drug-resistant bacterial infections are often due to severe pathogenic factors, phlegm and blood stasis, and a relative deficiency of the body's vital energy. This invention's herbal compound is a modified version of the *Qianjin Fang* (Thousand Gold Prescriptions) formulas: Weijing Tang, Ma Xing Shi Gan Tang, Tingli Dazao Xiefei Tang, and Pain-expelling Tang. It utilizes a combination of clearing, dispersing, resolving, descending, and harmonizing methods, effectively clearing heat from the lungs, resolving phlegm and removing blood stasis, and relieving wheezing. Among them, the Qianjin Weijing Decoction clears the lungs, drains pus, generates fluids, and resolves phlegm, targeting phlegm-heat and pus stasis in the lungs; the Ma Xing Shi Gan Decoction disperses lung heat, relieves asthma, and releases the exterior, targeting lung qi stagnation, cough, asthma, and fever; the Tingli Dazao Xiefei Decoction drains the lungs, promotes water metabolism, lowers qi, and relieves asthma, targeting phlegm-water stagnation in the lungs, cough, asthma, and chest fullness; and the Pain-Draining Decoction clears heat, detoxifies, drains pus, and reduces swelling, targeting lung abscesses with suppuration.

[0013] Furthermore, the formula uses reed rhizome, coix seed, peach kernel, and winter melon seed as the principal herbs, which is the core of the *Qianjin Fang* (Thousand Gold Prescriptions) Reed Stem Decoction. Its function is to clear the lungs and drain pus, resolve phlegm and remove blood stasis, targeting the root cause of phlegm-heat and blood stasis. Reed rhizome (reed stem) is sweet and cold, clearing the lungs, purging heat, and generating fluids, making it the most important of the principal herbs. Coix seed is sweet, bland, and slightly cold, clearing lung heat and draining dampness from the intestines and stomach, helping phlegm and dampness descend. Peach kernel invigorates blood and removes blood stasis, clearing blood stasis in the lung channels, embodying the principle of "treating phlegm and blood stasis simultaneously." Winter melon seed clears the lungs, resolves phlegm, and drains dampness and pus. These four herbs work together as the principal herbs, targeting the four major pathological products of the lungs: phlegm, heat, blood stasis, and pus, forming the foundation for clearing stagnation in the lungs.

[0014] The formula also uses ephedra, gypsum, apricot kernel, and lepidium seed as assistant herbs. This forms the core of the Ma Xing Shi Gan Tang and Ting Li Da Zao Xie Fei Tang, which functions to clear lung heat, lower qi, and relieve asthma, addressing the symptoms of impaired lung qi circulation. Ephedra is combined with gypsum; ephedra is pungent and warm, dispersing and opening up lung qi to relieve asthma; gypsum is pungent, sweet, and very cold, clearing heat from the lungs and stomach to generate fluids. The two, one warm and one cold, work synergistically, their pungent and cool dispersing properties focusing on clearing lung heat and promoting qi circulation. Apricot kernel is bitter and descending, lowering lung qi, stopping cough, and relieving asthma. Together with ephedra, they restore the lung's dispersing and descending functions. Lepidium seed is bitter, pungent, and very cold, with a strong effect, specifically for purging phlegm and fluid from the lungs and relieving asthma. It is used for severe cases of excessive phlegm and shortness of breath that prevent lying down. It complements the pus-draining and phlegm-resolving properties of the chief herb, Wei Jing Tang, enhancing its cleansing power.

[0015] The formula further uses Platycodon grandiflorus, prepared licorice root, fresh ginger, and jujube as adjuvant herbs. This is the core of the Pain-Expelling Decoction, which functions to soothe the throat, eliminate phlegm, and harmonize the effects of the other herbs. Platycodon grandiflorus is a "boat-like agent," which promotes lung function, soothes the throat, eliminates phlegm, and drains pus. It can carry the other herbs upwards to the lungs and assist Reed stem and Winter melon seed in draining pus and resolving phlegm. Prepared licorice root, jujube, and fresh ginger tonify qi and harmonize the middle jiao, protecting the spleen and stomach and preventing cold and drastic herbs from damaging the stomach qi. Licorice root and jujube can also harmonize the other herbs and moderate the harshness of Ephedra and Lepidium seed. Fresh ginger also helps Ephedra disperse external pathogens, and can also harmonize the middle jiao, stop vomiting, and resolve phlegm.

[0016] The formula promotes lung function, resolves phlegm and dampness, clears stagnation and turbidity, clears lung heat, resolves phlegm and drains pus, relieves asthma and stops coughing. It is suitable for the pathogenesis of lung infections and phlegm-heat accumulation in the lungs.

[0017] Verification has shown that the traditional Chinese medicine compound of this invention can effectively inhibit the proliferation of multidrug-resistant Pseudomonas aeruginosa, and has a significant effect on clearing drug-resistant bacteria. In addition, the traditional Chinese medicine compound of this invention can effectively improve the gross and pathological morphology of lung tissue, regulate the level of inflammatory factors, exert a significant anti-inflammatory effect, and achieve a good therapeutic effect on a rat model of pneumonia complicated by drug-resistant bacteria infection. Attached Figure Description

[0018] Figure 1 The results of colony counting in lung tissue homogenates from each group of rats are shown.

[0019] Figure 2 The gross changes in lung tissue of rats in each group are shown.

[0020] Figure 3The results of H&E staining of lung tissue from rats in each group are shown.

[0021] Figure 4 The changes in the expression of inflammatory factors in the lung tissue of rats in each group; compared with the control group, # P<0.05, ### P<0.001, #### P<0.0001; compared with the model group, **P<0.01, ***P<0.001.

[0022] Figure 5 The following are the results of multi-slice spiral CT scans of Cai's lungs before treatment, one week after treatment, and two months after treatment.

[0023] Figure 6 The results of multi-slice spiral CT scans of Wang's lungs before and after treatment. Detailed Implementation

[0024] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0025] Unless otherwise specified, the experimental methods used in the following examples or test cases are conventional methods.

[0026] Unless otherwise specified, all materials and reagents used in the following examples or test cases are commercially available.

[0027] Example 1

[0028] A traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection, the traditional Chinese medicine compound is composed of the following Chinese medicinal materials by weight: 30g of reed rhizome, 20g of coix seed, 5g of peach kernel, 30g of winter melon seed, 5g of apricot kernel, 5g of platycodon root, 10g of lepidium seed, 5g of prepared licorice root, 5g of ephedra, 20g of gypsum, 5g of jujube, and 5g of ginger.

[0029] The traditional Chinese medicine compound provided by this invention is used to prepare a drug for treating pneumonia complicated by multidrug-resistant bacterial infection. The drug is made from the above-mentioned weight of traditional Chinese medicinal materials as raw materials, supplemented with pharmaceutically acceptable excipients, and prepared into any one of granules, oral liquid, or decoction.

[0030] Example 2

[0031] The difference between this embodiment and Embodiment 1 is that:

[0032] The traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection consists of the following medicinal materials by weight: 60g of reed rhizome, 40g of coix seed, 25g of peach kernel, 60g of winter melon seed, 25g of apricot kernel, 25g of platycodon root, 30g of lepidium seed, 20g of prepared licorice root, 20g of ephedra, 40g of gypsum, 25g of jujube, and 25g of ginger.

[0033] Example 3

[0034] The difference between this embodiment and Embodiment 1 is that:

[0035] The traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection consists of the following medicinal materials by weight: 35g of reed rhizome, 20g of coix seed, 10g of peach kernel, 25g of winter melon seed, 10g of apricot kernel, 10g of platycodon root, 12g of lepidium seed, 9g of prepared licorice root, 9g of ephedra, 20g of gypsum, 9g of jujube, and 12g of ginger.

[0036] Example 4

[0037] The difference between this embodiment and Embodiment 1 is that:

[0038] The traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection consists of the following Chinese medicinal materials by weight: 40g of reed rhizome, 25g of coix seed, 10g of peach kernel, 40g of winter melon seed, 10g of apricot kernel, 10g of platycodon root, 15g of lepidium seed, 5g of prepared licorice root, 5g of ephedra, 25g of gypsum, 10g of jujube, and 10g of ginger.

[0039] Example 5

[0040] The difference between this embodiment and Embodiment 1 is that:

[0041] The traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection consists of the following Chinese medicinal materials by weight: 50g of reed rhizome, 35g of coix seed, 20g of peach kernel, 50g of winter melon seed, 20g of apricot kernel, 20g of platycodon root, 25g of lepidium seed, 15g of prepared licorice root, 15g of ephedra, 35g of gypsum, 20g of jujube, and 20g of ginger.

[0042] Example 6

[0043] The difference between this embodiment and Embodiment 1 is that:

[0044] The traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection consists of the following medicinal materials by weight: 42g of reed rhizome, 28g of coix seed, 12g of peach kernel, 40g of winter melon seed, 18g of apricot kernel, 18g of platycodon root, 18g of lepidium seed, 10g of prepared licorice root, 10g of ephedra, 25g of gypsum, 12g of jujube, and 14g of ginger.

[0045] Example 7

[0046] The differences between this embodiment and Embodiment 1 are as follows:

[0047] The traditional Chinese medicine compound for treating multi-drug resistant bacteria infection complicated with pneumonia is composed of the following traditional Chinese medicinal materials by weight: 45 g of reed rhizome, 30 g of coix seed, 15 g of peach kernel, 45 g of winter melon seeds, 15 g of almond, 15 g of platycodon root, 20 g of semen lepidii, 10 g of roasted licorice root, 9 g of ephedra, 30 g of gypsum, 15 g of Chinese date, and 15 g of fresh ginger.

[0048] Experimental Example

[0049] 1 Materials

[0050] 1.1 Bacteria

[0051] Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) was provided by the Clinical Laboratory of the First Affiliated Hospital of Henan University of Chinese Medicine. Before use, the concentration of MDR-PA in the logarithmic growth phase was adjusted to 9×10 8 Colony-forming unit (CFU) / mL.

[0052] 1.2 Experimental animals

[0053] 72 male SPF-grade SD rats, weighing 200±20 g, were provided by Beijing Speifu Experimental Animal Technology Co., Ltd. [SCXK (Beijing) 2019-0010] and were housed in the SPF-grade animal experiment center of the First Affiliated Hospital of Henan University of Chinese Medicine [SYXK (Henan) 2022-0004]. The feeding environment was a standard SPF environment (12-hour day-night cycle, temperature 22±2°C, humidity 55±5%). The experimental animals could freely eat and drink water. After 7 days of adaptive feeding, they were subjected to model intervention. The experimental procedures of this study strictly adhered to the international animal welfare ethics norms and were approved by the Experimental Animal Welfare Ethics Review Committee of the First Affiliated Hospital of Henan University of Chinese Medicine (Ethics review approval number: YFYDW2024047).

[0054] 1.3 Drugs and reagents

[0055] The traditional Chinese medicine compound preparation of the present invention (abbreviated as WMXHF): 45 g of reed rhizome, 30 g of coix seed, 15 g of peach kernel, 45 g of winter melon seeds, 15 g of almond, 15 g of platycodon root, 20 g of semen lepidii, 10 g of roasted licorice root, 9 g of ephedra, 30 g of gypsum, 15 g of Chinese date, and 15 g of fresh ginger. After decocting the compound with water and drying it, it was made into a powder and configured into a drug suspension with normal saline.

[0056] Positive control drug: Imipenem and cilastatin sodium for injection.

[0057] 2 Research methods

[0058] 2.1 Animal Model Preparation

[0059] Seventy-two rats were randomly divided into six groups: a blank control group, a model group, a low-dose compound group, a medium-dose compound group, a high-dose compound group, and an imipenem / cilastatin (IPM) group, with 12 rats in each group. After one week of acclimatization feeding, except for the blank control group, all other groups had bacterial suspension injected via endotracheal intubation to establish an MDR-PA pneumonia model. After 12 hours of fasting, the rats were anesthetized by intraperitoneal injection of 3% sodium pentobarbital (1 mL / kg). The rats were fixed in a head-up supine position, and after exposing the glottis, 9 × 10⁹ ml of the suspension was slowly injected via the trachea. 8 The rats were given a CFU / mL MDR-PA bacterial suspension (0.5 mL / rat) with an appropriate amount of air injected. The control group was injected with an equal volume of sterile saline. The rats were gently rocked from side to side and kept in a 45° supine position until they woke up.

[0060] 2.2 Grouping and Administration

[0061] One day after modeling, each group was administered medication according to the following regimen: the low-dose compound group was given 0.82 g·kg of the compound by gavage. -1 ·d -1 The compound preparation at medium dose was administered via gavage at a dose of 1.64 g / kg. -1 ·d -1 The high-dose compound group was administered 3.28 g / kg of the compound via gavage. -1 ·d -1 The IPM group received an intraperitoneal injection of imipenem / cilastatin 0.180 g / kg. -1 Rats in the control group and model group were administered the same volume of physiological saline by gavage. All groups were given the medication once a day for 7 consecutive days.

[0062] 2.3 Colony Counting of Lung Tissue Homogenate

[0063] After administration, rats in each group were euthanized by cervical dislocation, and lung tissue was collected. Changes in lung tissue were observed by the naked eye. Then, the middle lobe of the right lung was weighed and added to 1 mL of physiological saline in a sterile EP tube with steel balls. The mixture was homogenized and diluted 10-fold. Three appropriate gradients were selected and evenly spread on LB agar plates, with two parallel replicates for each gradient. The plates were incubated in a 37℃ biochemical incubator for 24 h. Colony characteristics were observed and colony counts were performed.

[0064] 2.4 Observation of lung tissue pathological morphology

[0065] After the administration of the drug, rats in each group were euthanized by dislocation of the neck. After ligation of the bronchus, the left lung was perfused with 4% paraformaldehyde for 20 min. After fixation for 72 h, the lungs were dehydrated and embedded to prepare 4 μm paraffin sections. Routine H&E staining was performed to observe the pathological changes in the alveoli and small airways.

[0066] 2.5 Detection of inflammatory factor levels in lung tissue

[0067] After the administration of the drug, rats in each group were euthanized by cervical dislocation. Six rats were randomly selected to have their lung tissue taken, which was ground into a homogenate, centrifuged to obtain the supernatant, and the levels of IL-6, IL-1β, IFN-γ, and TNF-α were detected using an ELISA kit.

[0068] 3. Observation Indicators and Results

[0069] 3.1 Colony Counting of Lung Tissue Homogenate

[0070] In vitro colony culture results showed that after inoculation of the model group homogenate, characteristic pale yellow, mucous-like colonies grew densely, indicating an extremely high load of drug-resistant bacteria and demonstrating the strong in vitro proliferation ability of drug-resistant strains. In the imipenem / cilastatin group, colony growth was effectively inhibited, with only a few scattered colonies observed, and the colony diameter reduced to less than 1 mm. Proliferative activity was weakened, and the elimination of drug-resistant bacteria was ideal. The different dosage groups of the traditional Chinese medicine showed a stepwise antibacterial effect: the high-dose group had the best antibacterial effect, with fewer colonies and a colony diameter reduced to about 1 mm; the medium-dose group showed significantly inhibited colony growth and a significantly reduced density, but not as good as the high-dose group; the low-dose group could reduce the number of colonies to some extent, with a colony diameter of about 1-2 mm, but the antibacterial effect was weaker than the medium- and high-dose groups and the Western medicine group. The results are as follows: Figure 1 As shown.

[0071] 3.2 Gross Changes in Lung Tissue

[0072] Grossly, the lung tissue of the control group rats was bright red, soft, with clear lobe contours, smooth surface without exudate, dry cut surface with regular structure, and no purulent secretions. In the model group rats, due to invasion by drug-resistant Pseudomonas aeruginosa, the lung tissue showed significant pathological changes, appearing grayish-green overall, hardened and less elastic, with obvious lobular swelling and congestion. Scattered or diffuse purulent nodules and exudative foci were visible on the surface, the cut surface was moist with blurred edges, and pale yellow or yellowish-green purulent secretions oozed upon compression. Consolidation areas were visible in some lobes, and the bronchial lumen was also filled with purulent secretions. The IPM group, as the control group for the western medicine, showed a more ideal gross improvement in lung tissue. Lobe swelling and congestion were significantly reduced, the number of purulent nodules and exudative foci on the surface was significantly reduced, the texture became softer, purulent secretions on the cut surface were significantly reduced, the area of ​​consolidation was reduced, with only slight residual congestion in some areas, and the overall gross morphology was close to normal. After intervention with different doses of traditional Chinese medicine, the gross lung tissue damage in rats in each treatment group showed a stepwise improvement: the medium and high dose groups showed the best improvement, with the lung tissue color basically returning to bright red, the texture becoming soft and elastic, the surface showing no obvious purulent nodules or exudates, the cut surface being dry and regular, without consolidation or purulent secretions, and the gross morphology being close to the control group; the low dose group showed the second best effect, with relief of lung lobe swelling and congestion, a significant reduction in surface purulent nodules and exudates, a softer texture than the model group, reduced purulent secretions on the cut surface, and a significant reduction in the area of ​​consolidation. Results are as follows. Figure 2 As shown.

[0073] 3.3 Pathological morphological changes in lung tissue

[0074] In the control group, the alveolar structure of rats remained intact, with no obvious breakage or fusion. No inflammatory exudate was observed in the alveolar cavities, and the alveolar and airway walls were of moderate thickness without edema, showing only occasional infiltration of a small number of inflammatory cells. In the model group, the lung tissue pathology of rats showed significant damage, with a large number of inflammatory cells infiltrating the lung parenchyma, significant edema and thickening of the alveolar walls, accompanied by alveolar rupture and fusion, and the alveolar cavities filled with a large amount of inflammatory exudate. Significant edema was observed in the peribronchial tissues, leading to varying degrees of luminal narrowing. The IPM group, serving as the control group for the western medicine treatment, showed a more ideal improvement in lung tissue pathology, with a significant reduction in inflammatory cell infiltration, a marked alleviation of alveolar wall edema and thickening, alveolar fusion, reduced airway narrowing, and near-complete clearance of inflammatory exudate. After intervention with different doses of traditional Chinese medicine, the pathological damage to the lung tissue of rats in all treatment groups was improved. The high- and medium-dose groups showed the best improvement, with alveolar structure approaching normal, and symptoms such as inflammatory cell infiltration, alveolar wall edema, and airway stenosis largely subsiding. The low-dose group showed the second best effect, with significant relief of the aforementioned pathological damage, a significant reduction in inflammatory exudate, and a decrease in alveolar fusion. Results are as follows... Figure 3 As shown.

[0075] 3.4 Changes in the expression of inflammatory factors in lung tissue

[0076] Compared with the blank group, the levels of inflammatory factors IL-6, IL-1β, IFN-γ, and TNF-α in the lung tissue of rats in the model group were significantly increased (P<0.05); compared with the model group, after intervention with different doses of traditional Chinese medicine, the levels of inflammatory factors IL-6, IL-1β, IFN-γ, and TNF-α in the lung tissue of rats in each treatment group were significantly decreased (P<0.01).

[0077] 4. Conclusion

[0078] The above experimental results show that the traditional Chinese medicine compound preparation of the present invention can effectively inhibit the proliferation activity of multidrug-resistant Pseudomonas aeruginosa, and has a significant effect on clearing drug-resistant bacteria; by effectively improving the gross and pathological morphology of lung tissue and regulating the level of inflammatory factors, it exerts a significant anti-inflammatory effect and achieves a good therapeutic effect on a rat model of pneumonia complicated by drug-resistant bacteria infection.

[0079] Application examples

[0080] Case 1:

[0081] Patient Cai, female, 35 years old, presented with symptoms such as cough, wheezing, and dyspnea, without fever or headache. A multi-slice spiral CT scan showed patchy and flocculent increased density shadows in both lungs, and a cystic transpleural lucid shadow in the lower lobe of the right lung; the hilar shadows were not enlarged. She was diagnosed with bilateral pneumonia. She was given the herbal decoction of this invention, composed of: 45g of reed rhizome, 30g of coix seed, 15g of peach kernel, 45g of winter melon seed, 15g of apricot kernel, 15g of platycodon root, 20g of lepidium seed, 10g of prepared licorice root, 9g of ephedra, 30g of gypsum, 15g of jujube, and 15g of ginger. One dose was prescribed daily, decocted in water to 400mL, taken twice daily (morning and evening) for two months. One week after treatment, the cystic lucid shadow in the lower lobe of the right lung gradually subsided, the bilateral pneumonia improved, and the clinical symptoms such as cough and wheezing were relieved. Two months after treatment, a multi-slice spiral CT scan showed that the cystic bright shadow in the lower lobe of the right lung had almost disappeared, and clinical symptoms such as cough and wheezing had disappeared. The patient was considered to be cured clinically. Figure 5 The images show the results of Cai's lung CT scans before treatment and one week and two months after treatment.

[0082] Case 2:

[0083] The patient, Mr. Wang, male, 76 years old, was diagnosed with wind-heat lung disease by traditional Chinese medicine. His clinical symptoms included cough, chest tightness, wheezing, and difficulty breathing, but no fever, dizziness, or headache. The multi-slice spiral CT scan showed increased and disordered lung markings in both lung fields, and reticular and patchy areas of increased density in the outer zones and lower lobes of both lungs. Solid nodular shadows were seen in the upper lobe of the left lung and the lower lobe of the right lung. He was diagnosed with bilateral pneumonia. The herbal decoction of this invention consists of the following ingredients: 45g of reed rhizome, 30g of coix seed, 15g of peach kernel, 45g of winter melon seed, 15g of apricot kernel, 15g of platycodon root, 20g of lepidium seed, 10g of prepared licorice root, 9g of ephedra, 30g of gypsum, 15g of jujube, and 15g of ginger. One dose is taken daily, decocted in water to 400mL of liquid, and taken twice a day, morning and evening. After two weeks of continuous use, the multi-slice spiral CT scan showed that the interstitial pneumonia in both lungs was significantly relieved, and the symptoms such as cough and chest tightness were significantly improved. Figure 6 The results of lung CT scans before and after treatment for Mr. Wang.

[0084] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection, characterized in that, The herbal compound consists of the following herbs by weight: 30-60g of reed rhizome, 20-40g of coix seed, 5-25g of peach kernel, 30-60g of winter melon seed, 5-25g of apricot kernel, 5-25g of platycodon root, 10-30g of lepidium seed, 5-20g of prepared licorice root, 5-20g of ephedra, 20-40g of gypsum, 5-25g of jujube, and 5-25g of ginger.

2. The traditional Chinese medicine compound formula for treating pneumonia complicated by multidrug-resistant bacterial infection as described in claim 1, characterized in that, The herbal compound consists of the following herbs by weight: 40-50g of reed rhizome, 25-35g of coix seed, 10-20g of peach kernel, 40-50g of winter melon seed, 10-20g of apricot kernel, 10-20g of platycodon root, 15-25g of lepidium seed, 5-15g of prepared licorice root, 5-15g of ephedra, 25-35g of gypsum, 10-20g of jujube, and 10-20g of ginger.

3. A traditional Chinese medicine compound for treating pneumonia complicated by multidrug-resistant bacterial infection as described in claim 1, characterized in that, The herbal compound consists of the following herbs by weight: 45g of reed rhizome, 30g of coix seed, 15g of peach kernel, 45g of winter melon seed, 15g of apricot kernel, 15g of platycodon root, 20g of lepidium seed, 10g of prepared licorice root, 9g of ephedra, 30g of gypsum, 15g of jujube, and 15g of ginger.

4. The use of the traditional Chinese medicine compound according to any one of claims 1 to 3 in the preparation of a medicament for treating pneumonia complicated by multidrug-resistant bacterial infection, characterized in that, The drug is made from the above-mentioned weight of Chinese medicinal herbs as raw materials, supplemented with pharmaceutically acceptable excipients, and prepared into any one of granules, oral liquids, or decoctions.